NIH Grants Biotech Firm Monopoly on Cutting-Edge Cancer Detection Tech
Published Date: 11/19/2025
Notice
Summary
The National Institutes of Health plans to give BioncoDx, LLC an exclusive license to use special methods for diagnosing and predicting cancer. This means BioncoDx will have the sole right to develop and sell these cancer-related technologies. If you want to comment or apply for a license, you need to act by December 4, 2025.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Exclusive Urine-Based Cancer Test License
The NIH plans to grant BioncoDx, LLC an exclusive license to develop, manufacture, and commercialize Food and Drug Administration (FDA) premarket approval tests that use four urine biomarkers—creatine riboside, metabolite 561+, cortisol sulfate, and N-acetylneuraminic acid—to detect and prognose cancers (examples listed include lung, breast, colorectal, kidney/bladder, prostate, liver, stomach, pancreatic, GYN, and brain). The notice describes this technology as a unique, non-invasive screening and diagnostic tool that can detect cancers at an early stage using urine samples and that urine sampling minimizes patient discomfort compared with invasive methods.
Sole Commercial Rights for BioncoDx
The prospective license would give BioncoDx the sole (exclusive) right to practice the listed patent rights worldwide where patent rights exist for the specified field of use: developing, manufacturing, and commercializing FDA PMA tests using the named biomarkers for screening/diagnosing the listed cancers. After a negotiated period, the exclusive field of use will be reduced to a subset of three cancer indications and will include strict developmental benchmarks for each indication.
Prospective License Will Be Royalty‑Bearing
The notice states the prospective exclusive license will be royalty-bearing. The notice also states that the license may be granted unless, within fifteen (15) days from the date of the published notice, the National Cancer Institute receives written evidence and argument that the grant would not be consistent with applicable law.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13802 — Government Owned Invention Available for License: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
The National Institutes of Health is offering special mouse strains that help study a rare heart rhythm disorder called CPVT. These mice let scientists explore how a key heart gene works and test new gene therapies. Researchers interested in this tool can access it now—no patents, just pure science ready to speed up discoveries!
2026-13612 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review and decide on important health research grant applications. These meetings keep sensitive info private to protect personal and commercial secrets. Researchers applying for grants and the public can expect no changes in funding timing or amounts, just careful, confidential reviews.
2026-13480 — Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.
2026-13479 — Government Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infection
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
2026-13337 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on July 24, 2026, to review and evaluate important grant applications related to cancer, imaging, eye diseases, and reproductive health. These meetings protect private info and trade secrets, so they’re not open to the public. Researchers and organizations applying for grants should note the dates as these reviews impact funding decisions.
2026-13311 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review grant applications and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants or contracts should watch these dates closely, as funding decisions could impact their projects and budgets.
Previous / Next Documents
Previous: 2025-20289 — Recertification of Cook Inlet Regional Citizens' Advisory Council
The Coast Guard has officially renewed the Cook Inlet Regional Citizens' Advisory Council (CIRCAC) for another year, from September 1, 2025, to August 31, 2026. This group keeps an eye on oil activities in Cook Inlet, Alaska, and since there were no big changes in their latest application, their recertification was smooth and quick. Local communities and environmental watchers can keep counting on CIRCAC’s watchful role without any new fees or delays.
Next: 2025-20291 — Agency Information Collection Activities: Comment Request on Burden Related to Superfund; Imported Substances; Procedures for Filing a Petition
The IRS wants your thoughts on how hard it is to ask if certain imported substances should be taxed or not under Superfund rules. This affects businesses dealing with these substances and could change how paperwork is handled, possibly saving time and money. Make sure to send your comments by January 20, 2026, to help shape the process!